Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to get liver surgery patients home days earlier

NCT ID NCT05879159

Symptom relief Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether an accelerated recovery program can safely shorten hospital stays for 36 adults undergoing minimally invasive liver surgery. Participants must have a tumor suitable for a specific type of liver resection, no cirrhosis, and live within 50 miles of the medical center after surgery. The program focuses on speeding up recovery while monitoring for any side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Tumor amenable to MIS Kawaguchi-Gayet grade I hepatectomy (see figure 1 below) * No evidence of cirrhosis (based on imaging, evidence of portal hypertension, clinical features, or laboratory results) * No significant cardiopulmonary disease that would prevent patients from undergoing MIS resection * Ability to stay within 50 miles of medical center for immediate postop period * Age of 18 years or above - because no adverse event data are currently available on enhanced recovery and early discharge after hepatic resection for patients \<18 years of age, children are excluded from this study * Ability to understand and the willingness to sign a written informed consent document * Non-English-speaking patients are eligible for participation Exclusion Criteria: Patients who will be excluded include those with: * Tumors NOT amenable to MIS Kawaguchi-Gayet grade I hepatectomy * Tumors not amenable to MIS or Robotic-assisted surgical resection * Evidence of Cirrhosis on imaging, clinically, or lab testing * Inability to stay within 50 miles of the Cancer Center in the immediate post-operative period * Age below 18 years * Inability to consent for trial/protocol * Patients who are pregnant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

liver and intrahepatic bile duct neoplasm liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.